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Abstract
Patients with severe heart failure (HF), who are not eligible for cardiac transplantation and receive op-
timal medical management, based mainly on the use of pharmacological treatment and devices such as 
resynchronization therapy (implantable cardioverter-defibrillator), achieve poor clinical outcomes and 
constitute a group with extremely poor prognosis. Currently, the technology used in the latest generation 
left ventricular assist devices (LVADs), such as the HeartMate 3, makes it possible to achieve patient 
survival at the level obtained by patients after heart transplantation, and they can be used not only in 
patients eligible for heart transplantation as a bridge to transplant, but also in those with significantly 
worse prognosis, who are ineligible for heart transplantation as destination therapy. 
The objective of this publication is to present recommendations from experts in cardiology and cardiac 
surgery, supported by clinical trial results, on the use of LVADs as a destination therapy in HF patients 
who are not eligible for cardiac transplantation. The paper also presents the issue of cardiac transplan-
tation and extracorporeal membrane oxygenation therapy in Poland, as well as current challenges faced 
by interventional cardiology and cardiac surgery in Poland. (Cardiol J 2020; 27, 6: 693–704)
Key words: heart failure, left ventricular assist device, destination therapy,  
extracorporeal membrane oxygenation, dilated cardiomyopathy
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Introduction
The following recommendations are based 
on presentations and discussions that took place 
during the Advisory Committee meeting organized 
in collaboration with the ‘Quo Vadis Cardiologia?’ 
initiative. The goal was to gather the opinions of 
leading experts (16 experts in total) in the fields of 
conservative cardiology, interventional cardiology, 
electrophysiology, and cardiac surgery regard-
ing aspects of the use of left ventricular assist 
devices (LVADs) as a destination therapy (DT) 
among Polish patients. In addition, the situation of 
transplantation procedures and the most important 
challenges of interventional cardiology and cardiac 
surgery in Poland were discussed [1]. 
LVADs as destination therapy
In a selected group of patients with heart fail-
ure (HF), mechanical circulatory support (MCS) 
may help to achieve sustained improvements in 
quality of life and life expectancy. While for many 
patients the use of MCS is still a bridge to trans-
plant or to recovery, for those with irreversible 
permanent lesions, MCS is a DT due to the insuf-
ficient number of donors and increasingly improved 
technical solutions [2–4]. This applies primarily to 
patients with severe HF:
 — with accompanying renal failure — high risk of 
dialysis after orthotopic heart transplantation;
 — who are significantly overweight (over 100 kg) 
— difficulty in obtaining a donor;
 — with persistent pulmonary hypertension high 
risk of primary graft failure after transplantation.
Continuous-flow left ventricular assist devices 
(CF-LVADs) revolutionized the management of 
HF patients. These compact, fully implantable 
cardiac pumps are able to provide a significant 
increase in survival and improve the function and 
quality of life in a selected group of patients. For 
such a large group of people facing a high risk of 
short-term mortality and a small chance of heart 
transplantation, implantation of CF-LVADs gives 
the greatest hope. In patients with a CF-LVAD the 
annual survival rate is 82%, while in patients with 
pulsatile flow devices it is 61% [5, 6].
INTERMACS is an American registry of 
patients in which data on MCS are collected from 
mandatory submissions regarding LVAD implanta-
tions in the United States (US) and, on a voluntary 
basis, from some other countries or centers. The 
latest INTERMACS report, published in 2017, 
states that over 22,000 implantations of different 
MCS systems have been recorded in the last dec-
ade, of which 90% are CF-LVADs. On the basis of 
the available data, we know today that:
 — 25% of the MCS devices are implanted as 
a bridge to transplant;
 — 24% of the MCS devices are implanted to 
improve the patients’ clinical status to be 
considered as a bridge to candidacy;
 — 51% of the MCS devices are implanted under 
DT (compared to 3.9% in 2009) [7].
Over several decades, technical develop-
ment of LVADs designed for long-term support 
has been observed. New solutions in the field 
of pump drive construction, miniaturization, and 
materials, as well as battery life and performance 
were implemented. This is directly related to 
a significant reduction in thromboembolic compli-
cations, bleedings, and infections, which makes 
these devices safe for permanent use and reduces 
hospital admissions. We can now distinguish three 
LVAD generations. First-generation LVADs include 
HeartMate I, LionHeart, and Novacor. Second-
generation devices are DeBakey VAD, Incor, Jarvik 
2000, and HeartMate II. The third and most recent 
LVAD generation includes devices such as Heart-
Ware or HeartMate 3 [8].
The two US Food and Drug Administration-
approved and CE-marked LVADs predominantly 
used in long-term treatment are HeartWare and 
HeartMate 3. HeartMate 3 replaced the previous 
HeartMate II (a continuous-flow line pump) [9]. 
Implantation of the ventricular support system 
is a procedure performed in patients with severe 
and reversible (or irreversible) heart damage, who 
have exhausted all alternative treatment options, 
i.e. no other cardiac surgery can be performed, 
and pharmacological treatment cannot be ex-
pected to stop further disease progression. The 
LVAD is implanted through a sternotomy or using 
a minimally invasive technique (through left-sided 
mini-thoracotomy combined with right-sided up-
per mini-thoracotomy or mini-sternotomy) and 
involves the implantation of a device that ensures 
blood circulation by pumping it out of the left 
ventricle and into the aorta. The procedure is 
performed with extracorporeal circulation or, in 
selected cases, without its use. Long-term LVADs 
are used for longer than a month. Depending on 
the type of device, the drive system is pneumatic 
or electrical. 
The LVAD that will ensure the best effective-
ness as a DT in patients not eligible for a heart 
transplant should have, above all, a very good 
hemocompatibility profile:
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 — achieving long survival times; 
 — which will be free from hemocompatibility-
related events such as a stroke, pump throm-
bosis, hemolysis, or other thromboembolic 
events (Table 1). 
At the same time, this translates into a sig-
nificant improvement in the functional status and 
quality of life in this group of patients.
Advances in the management of heart disease, 
in particular in the area of LVAD implantation, 
has led to the development of pulse and then 
continuous flow devices. The latest-generation 
LVADs — centrifugal with continuous flow — are 
fully implanted into the pericardial sac. In these 
devices, the rotors are magnetically levitated, 
which eliminates the spaces not washed by blood, 
which used to be the main source of thromboem-
bolic complications. Miniaturization of the devices 
has improved patient quality of life and functioning 
outside hospital. In some groups of patients with 
end-stage HF, who are not candidates for ortho-
topic heart transplantation, but whose expected 
survival is > 1 year in good functional condition, 
left ventricular support can be considered as a DT 
to reduce clinical signs indicative of the risk of 
rehospitalization and premature death (European 
Society of Cardiology [ESC] class IIa, level B rec-
ommendation). This safe, reliable, durable, and 
implantable mechanism supporting the function of 
the left ventricle is considered an effective device 
for DT [10]. Using LVADs is beneficial in terms 
of the improvement of hemodynamic parameters 
(consisting of an increase of ejection fraction and of 
cardiac index, reduction of pulmonary wedge pres-
sure and left ventricular end-diastolic dimension) 
and, consequently, improvement also of clinical 
parameters (improvement in functional class — 
New York Heart Association [NYHA], quality of 
life, prolonged life expectancy) [6]. 
The 2016 ESC guidelines for diagnosis and 
treatment of acute and chronic HF contain a list of 
indications for which MCS devices are implanted 
(Table 2) and recommendations for the use of MSC 
in patients with refractory HF (Table 3).
The selection of an appropriate device depends 
on many factors, including the expected duration 
of treatment, the need for correct ventricular sup-
port, and the patient’s body surface area. It is very 
important to exclude absolute contraindications 
to ventricular assist device (VAD) implantation. 
However, each case is assessed individually, and 
the listed criteria are drawn up solely for reference. 
At times, VADs are implanted in patients who do 
not yet meet the above criteria [3].
Hemodynamic criteria for the use of VADs 
include: 
 — cardiac index < 2 L/min/m2;
 — systolic blood pressure (SBP) < 90 mmHg;
 — pulmonary capillary wedge pressure (PCWP 
> 20 mmHg;
 — diuresis < 20 mL/h [11].
Patients with severe symptoms persisting 
for more than 2 months, despite optimal medical 
and implantable device therapy, and more than 
one of the following, are candidates for LVAD 
implantation:
 — left ventricular ejection fraction (LVEF) 
< 25% and, if measured, peak oxygen VO2 
< 12 mL/kg/min;
 — ≥ 3 hospitalizations for HF within the last 
12 months without an obvious precipitating 
cause;
 — dependence on IV inotropic therapy;
 — progressive end-organ dysfunction (worsen-
ing renal and/or liver function) due to re-
duced perfusion rather than inadequate ven-
tricular filling pressure (PCWP ≥ 20 mmHg 
and SBP ≤ 80–90 mmHg or cardiac index 
≤ 2 L/min/m2);
 — absence of severe right ventricular dysfunction, 
including severe tricuspid regurgitation [11].
The reference candidate for an LVAD is 
a patient with chronic, congestive left ventricular 
failure, with a history of frequent decompen-
sation, requiring intravenous inotropic therapy 
(INTERMACS 3: dependent stability) at the time of 
qualification or in the past, with normal or slightly 
impaired right ventricular function. In patients with 
HF exacerbation, who require escalation of drug 
therapy or the use of other MCS devices (IABP or 
Table 1. Key parameters of long-term mechani-
cal circulatory support (LT-MCS) devices [7].
LT-MCS characteristic
Ability to generate adequate blood flow and pressure
Easy replacement of components that may fail
Easy system removal during heart transplantation 
or explantation after the failing heart’s function is 
restored
Small size
Fully implantable and easily renewable power source
Durability
No immunogenicity
Low degree of hemolysis
Low risk of infectious complications
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ECMO; INTERMACS class 2), LVAD implantation 
is a life-saving method with proven efficacy and 
a good safety profile. 
In patients with milder disease — defined by 
INTERMACS as groups 4–5 — LVAD implanta-
tion may be considered as a prevention of frequent 
hospitalizations due to HF to improve prognosis 
and quality of life, especially in the population of 
patients with contraindications for transplantation 
or whose expected waiting time for the organ (e.g. 
obese patients) is very long [12]. 
Contraindications for VAD implantation in-
clude: 
 — irreversible advanced hepatic or renal failure;
 — active systemic infection;
 — chronic obstructive pulmonary disease;
 — disseminated cancer;
 — clinically significant purpura;
 — cerebrovascular disease [3].
Unfortunately, despite the use of advanced 
technology, LVADs are not free of defects, and 
their implantation may result in early and late 
complications.
The main complications in patients with an 
implanted LVAD are driveline infections occur-
ring in about 30% of patients and, less commonly, 
generalized device-related infections. There may 
be a risk of infection at any time after implantation, 
but it usually occurs between week 2 and month 
12 after the procedure. The infections are usually 
caused by Gram-positive (Staphylococcus aureus, 
epidermidis) or, less frequently, Gram-negative 
bacteria (Pseudomonas aeruginosa, Enterobacter, 
and Klebsiella sp.) and fungi. In individual cases 
Table 2. Indications for mechanical circulatory support (2016 ESC Guidelines for the Diagnosis and 
Management of Acute and Chronic Heart Failure) [11].
Indication Rationale
Bridge to decision (BTD)/ 
/bridge to bridge (BTB)
Use of short-term MCS (e.g. ECLS or ECMO) in patients with cardiogenic shock until 
stabilization of hemodynamics and organ perfusion, exclusion of contraindications 
to long-term MCS (brain damage after resuscitation), and evaluation of additional 
therapeutic options including long-term ventricular assist device therapy and heart 
transplant
Bridge to candidacy (BTC) Use of MCS (usually LVAD) to improve end-organ function to make an ineligible  
patient eligible for a heart transplant
Bridge to transplant (BTT) Use of MCS (LVAD or BiVAD) to keep patients who are at high risk of death alive  
until a donor organ is available
Bridge to recovery (BTR) Use of MCS (typically LVAD) to keep patients alive until cardiac function recovers 
sufficiently and removal of MCS is possible
Destination therapy (DT) Long-term use of MCS (LVAD) as an alternative to heart transplantation in patients 
with end-stage heart failure ineligible for transplantation or for long-term waiting  
for heart transplantation
BiVAD — biventricular assist device; ECLS — extracorporeal life support; ECMO — extracorporeal membrane oxygenation; LVAD — left  
ventricular assist device; MCS — mechanical circulatory support
Table 3. Recommendations for the implantation of mechanical circulatory support in patients with  
refractory heart failure (2016 ESC Guidelines for the Diagnosis and Management of Acute and Chronic 
Heart Failure) [11].
Class Level Recommendation
IIa C LVADs should be considered in patients with end-stage HFrEF, despite optimal medical therapy 
and device therapy, who are eligible for cardiac transplantation in order to improve symptoms, 
and reduce the risk of heart failure hospitalization and the risk of premature death (BTT).
IIa B LVADs should be considered in patients with end-stage HFrEF, despite optimal medical (mainly 
ACEI or sacubitril/valsartan, beta-blockers, and MRA) and device therapy (e.g. implantable car-
dioverter defibrillator and/or cardiac resynchronization therapy), who are not eligible for cardiac 
transplantation, to reduce the risk of premature death (destination therapy)
ACEI — angiotensin converting enzyme inhibitor; BTT — bridge to transplant; HFrEF — heart failure with reduced ejection fraction; LVADs — 
left ventricular assist devices; MRA — mineralocorticoid receptor antagonist
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infection may lead to the development of bacte-
remia, sepsis, or endocarditis. Sepsis developing 
in patients with MCS promotes the formation 
of embolisms in the central nervous system or 
multiple organ failure, and it is the major cause of 
death. Therefore, the driveline exit site requires 
particular care. Dressings should be changed in 
fully aseptic conditions (masks, sterile gloves), 
washed with mild antibacterial soap and sterile 
saline, then covered with a sterile dressing. In 
addition, the driveline itself should be protected 
from excessive movement to minimize the risk of 
mechanical trauma [13]. Currently, in the event 
of failure of antibiotic therapy, surgical driveline 
repositioning is effectively used to treat infection 
in the exit site area. Heart transplantation is the 
ultimate treatment option in this situation [1].
Another significant complication is gastro-
intestinal bleeding or bleeding into the central 
nervous system, which is usually more severe. On 
the one hand, it is associated with the use of anti-
coagulants (warfarin and acetylsalicylic acid), and 
on the other hand, with changes in the circulatory 
system likely caused by less physiological continu-
ous flow in the majority of modern circulatory sup-
port systems. The incidence of this bleeding can 
be reduced up to two-fold through telemonitoring. 
Daily international normalized ratio measurement 
can eliminate the risk of bleeding [1].
Moreover, the risk of device dysfunction 
caused by the formation of blood clots, damage to 
the driveline, or other electromechanical causes 
cannot be ignored [14]. The negative effects of 
thrombosis and its incidence may be limited by 
daily monitoring of the LVAD patient via telehealth 
technology [1].
An example of a telehealth system is Re-
medizer, which is an application used to monitor 
patients’ health with LVADs after hospitalization 
[15], developed in cooperation with the National 
Institute of Cardiology of the Primate of the Mil-
lennium Cardinal Stefan Wyszynski in Warsaw. 
Patients use mobile devices to independently moni-
tor pump parameters and vital signs such as blood 
pressure, weight, and body temperature, as well 
as blood coagulability, and to control the medica-
tions intake. The data are automatically sent to the 
monitoring center, where the coordinating person 
conducts a thorough assessment of the treatment 
and makes decisions on medical interventions if 
the patient’s health state causes any concern [15]. 
According to data from the 2017 INTERMACS 
report, only about 20% of patients receiving MCS 
did not experience serious adverse events, such 
as infections, bleeding, stroke, device dysfunction, 
or death in the 3 years of follow-up. However, the 
patients’ quality of life significantly improved in 
the first 3 months. This improvement without seri-
ous adverse events is later maintained at a similar 
level. Paradoxically, patients receiving long-term 
LVAD treatment often do not agree to the proposed 
heart transplant, fully approving their assisted 
functioning. In some patients the improvement 
is so spectacular that the conversion from NYHA 
class IV to class I/II is achieved, enabling outpatient 
treatment with supportive care and even removal 
of the device [7].
HeartMate 3 — third-generation LVAD
The HeartMate (HM) 3 LVAD is the most 
recent third-generation pump used for long-term 
cardiac support in patients with severe HF, which is 
usually irreversible. The device is used as a bridge 
to transplant, which enables the patient to survive 
until a heart transplant is performed. It can also be 
used as a DT in patients with contraindications for 
cardiac transplantation. The HM 3 LVAD, which 
replaced the previous HM II axial flow pump, is 
smaller than the earlier pneumatic pumps and 
therefore easier for the surgeon to implant. It is im-
planted into the left ventricle of the heart and helps 
to support the patient’s heart for a period of several 
weeks up to many years [5]. The HM 3 LVAD par-
tially mimics the pulse rate, periodically increasing 
rotations. This is important because the natural 
blood flow has a pulsating character and as such 
determines the proper function of the endothelium 
of the blood vessels. Implantable circulatory sup-
port models usually provide continuous flow. This 
flow is thought to be responsible for distant VAD 
complications (e.g. hemorrhagic, thromboembolic 
events). That is why such high hopes are associated 
with the latest third-generation pumps, such as 
HM 3, in which the flow rate changes every 2 s, 
creating a ‘pulsation’ that mimics the natural blood 
flow in the human body. This solution contributes 
to the reduction of the number of complications re-
lated to the implantation or use of the device [5, 6].
LVAD HeartMate 3 as DT in clinical trials
The randomized clinical trial MOMENTUM 3 
compared the clinical efficacy and safety of HM 3 
LVAD with HM 2 LVAD in patients with severe 
HF. Participants were enrolled regardless of the 
indication for the device implantation; however, 
in the results analysis the data were stratified by 
the indication for implantation. Finally, approxi-
mately 60% of the patients who enrolled in the 
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MOMENTUM 3 trial had an LVAD implanted as 
a DT. These participants were not eligible for heart 
transplantation (Table 4) [6].
The primary endpoint of the MOMENTUM 3 
study was a 2-year event-free experience (a disa-
bling stroke or reoperation to replace or remove 
a malfunctioning device). A disabling stroke was 
defined as a modified Rankin score > 3. 
Patients not eligible for a transplant, who 
received the HM 3 device as a DT, achieved 
a 2-year event-free survival of 73.2%, which was 
significantly higher compared to 58.7% in patients 
with an HM 2 device. The likelihood of an event 
occurrence (a disabling stroke or reoperation to 
replace or remove a malfunctioning device) was 
almost two times lower for patients implanted with 
an HM 3 pump than for patients implanted with an 
HM 2 (hazard ratio [HR] = 0.61; 95% confidence 
interval [CI] 0.46–0.81; p = 0.0006). 
The use of the HM 3 device lowered the risk of 
adverse events in the form of a disabling stroke or 
reoperation, in order to replace/remove a malfunction-
ing device in the population of patients not eligible 
for heart transplantation, who received the LVAD as 
a DT at a level comparable to that in the population 
of patients who received the device as a bridge to 
transplant/bridge to candidacy (BTT/BTC) (HR = 0.61 
and HR = 0.62, respectively; 95% CI 0.40–0.94; p = 
= 0.02). Similar effectiveness of the HM 3 LVAD was 
demonstrated in the DT and BTT/BTC populations in 
terms of the 2-year event-free survival, 2-year overall 
survival, survival at 2 years free of stroke, and survival 
at 2 years free of pump thrombosis (Table 5).
Although no patient included in the MOMEN-
TUM 3 study was NYHA class I or II, as early as 
at 3 months post implantation of the HM 3, the 
functional status of 70% of patients improved and 
they were classified as NYHA class I or II. During 
the 2 years of follow-up, the percentage of patients 
with NYHA class I or II increased gradually and 
reached 80% at 2 years post implantation of the 
HM 3 LVAD, regardless of the indication, DT, or 
BTT/BTC (vs. baseline [p < 0.0001]). 
In patients with the HM3 LVAD, an improve-
ment from baseline in the 6-minute walking test 
was observed, irrespective of the intended goal of 
LVAD use: DT or BTT/BTC (p < 0.0001).
The quality of life based on EQ-5D-5L VAS 
form improved significantly at 3 months post im-
plantation of the HM3 LVAD (from the baseline 
value of 50 to 72) and was sustained for 2 years 
after pump implantation, achieving a score of 76 
after implantation of the HM3 pump and at the 
end of the follow-up, irrespective of the intended 
Table 4. Distribution of patients according to the indication for use of the HeartMate 3 (HM3) or the 
HeartMate 2 (HM2) pump in the MOMENTUM 3 study [6].
Indication for LVAD implantation HM3 (n = 515) HM2 (n = 505) Total (n = 1020)
BTT (bridge to transplant) 112 (22%) 120 (24%) 232 (23%)
BTC (bridge to candidacy) 86 (17%) 78 (15%) 164 (16%)
1. Likely to be candidates for a heart transplant 45 (8%) 43 (9%) 88 (9%)
2. Moderately likely to be candidates for a heart  
    transplant
32 (6%) 33 (7%) 65 (6%)
3. Unlikely to be candidates for a heart transplant 9 (2%) 2 (0.3%)  11 (0.8%)
DT (destination therapy): patients who are ineligible  
for a heart transplant
317 (62%) 307 (60%) 624 (61%)
LVAD — left ventricular assist device
Table 5. Comparison of the clinical effectiveness of the HeartMate 3 left ventricular assist device  
implanted in the destination therapy (DT) or bridge to transplant/bridge to candidacy (BTT/BTC)  
indication in the MOMENTUM 3 study.
Endpoint DT (n = 624) BTT/BTC (n = 396)
2-year event-free survival 73.2% 76.8%
2-year overall survival 76.7% 82.7%
Survival at 2 years free of stroke 88.1% 89.2%
Survival at 2 years free of pump thrombosis 97.5% 99.4%
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goal of LVAD use: DT or BTT/BTC (vs. baseline 
[p < 0.0001]).
Currently, the technology used in the HM 3 
pump allows patient survival at the same level 
of patients after heart transplantation and ena-
bles its use not only in patients eligible for heart 
transplantation as a BTT, but also in patients with 
considerably worse prognosis, i.e. not eligible for 
a heart transplantation as a DT. An important point 
is that patients with an implanted HM 3 LVAD as 
DT can achieve high clinical outcomes comparable 
to those in the group of patients receiving such 
treatment as a BTT/BTC.
Funding
Obtaining public financing of DT depends on 
creating a separate guaranteed health service, 
introducing uniform criteria for qualifying the 
patient to obtain this benefit, and making the pro-
cedure independent of the currently financed heart 
transplantation service. While under the ordinance 
of the Minister of Health of November 12, 2015, 
there were no restrictions on the use of LVAD 
therapy as DT, and the qualification for obtaining 
this service by the patient still remains associated 
with the transplantation procedure. Therefore, it 
is not clear from a legal point of view whether it 
is necessary to evaluate the clinical condition of 
the patients in terms of their suitability for cardiac 
transplantation during the process of qualification 
for an LVAD implantation. The ambiguity of these 
legal regulations in practice discourages healthcare 
providers from making decisions about LVAD im-
plantation regardless of their patients’ compliance 
with eligibility criteria for a heart transplant.  
It is necessary to separate the LVAD implan-
tation procedure as DT from the item currently 
described as highly specialized services. A change 
in the description of this service can be performed 
either by changing the description of the current 
highly able 4 service or by creating a new, separate 
basket of services including only the implantation 
of LVADs as DT. Taking into account the available 
clinical data and the premises for financing public 
health services, the creation of a new basket of 
services including exclusively the implantation 
of LVADs as a DT is an optimal solution for the 
system.
Polish guidelines for MCS
In Poland, the management procedures relat-
ing to HF patients are developed by the College 
of Family Physicians and the Working Group on 
Heart Failure of the Polish Cardiac Society. The 
current treatment protocol is described in the 2017 
guidelines. The guidelines were developed based 
on the 2016 ESC recommendations, which were 
also adopted by the Polish Cardiac Society. The 
2017 guidelines developed by the College of Family 
Physicians and the Polish Cardiac Society recom-
mend the use of LVADs in treatment-resistant 
patients who are classified with American College 
of Cardiology/American Heart Association (ACC/ 
/AHA) stage D HF [16].
In order to change the negative statistics for 
HF patients in Poland, the KONS (‘Comprehensive 
care for patients with heart failure’) system has 
been developed. Its introduction is expected to re-
sult in improved life expectancy, a reduced number 
of hospitalizations, decreased sickness absence, 
improved quality of life, and reduced indirect costs 
resulting from incapacity for work and sickness 
absenteeism (Social Insurance Institution [ZUS]). 
The main goal of the undertaking is to limit the ef-
fects of HF in Poland. The scope of the intervention 
includes the identification of HF symptoms, then 
diagnostics, therapy, rehabilitation, and long-term 
and palliative care [17, 18]. 
Eligibility criteria for patients and centers 
for the use of LVAD DT
According to clinical experts, all LVADs should 
be implanted as DT, which means that patients with 
an LVAD should not undergo a heart transplant un-
less specific indications exist. A heart transplantation 
in an LVAD patient is indicated when the individual 
presents with right ventricular failure and device- or 
driveline-related infection that cannot be treated 
surgically and/or with antibiotics. Hearts should be 
reserved for patients in a younger age group [1].
Clinical experts believe that pulmonary hy-
pertension is not an absolute contraindication to 
LVAD implantation (it is sometimes indicative of 
a good condition of the right ventricle) but is a classic 
contraindication for a heart transplant. In addition, 
the age of patients should not be a factor determin-
ing their access to an LVAD. However, increasing 
the age of patients qualifying to receive an LVAD 
without setting an age limit will result in an in-
creasing risk of complications. The best outcomes 
following an LVAD pump implantation are achieved 
in patients in INTERMACS 3 or 4 profiles — for 
instance, considerable quality of life improvement 
is achieved. Patients with cardiomyopathy and 
a history of cancer are usually not eligible for car-
diac transplantation. In these patients, an LVAD is 
the optimal solution [1]. 
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LVAD therapy should be contraindicated in 
patients with addiction to alcohol (alcoholic car-
diomyopathy) or other psychoactive substances, if 
they were used at least a year prior to the planned 
intervention. In addition, a patient with an LVAD 
should have support of a family member, who 
should be trained in using the device and advised 
about possible adverse events. 
Experts have agreed that it is necessary to 
create a roadmap describing measures needed to 
introduce LVADs as DT in Poland, from establish-
ing the patient eligibility criteria (eligibility algo-
rithm), through conducting healthcare personnel 
training on LVAD patient care (e.g. paramedics, 
primary care physicians in the patient’s region of 
residence), to preparing society and hospital wards 
for the increasing number of LVAD patients. 
An important element of postoperative care 
for patients with LVADs is the treatment of device-
related complications, which should be managed in 
dedicated, specialized or initial centers depending 
on the complication, its extent, and prognosis. 
Many LVAD complications (e.g. gastrointestinal 
bleeding, stroke) do not require treatment at an im-
plantation center. The main complication requiring 
treatment at the initial center is driveline infection.
It is recommended that LVAD pump implan-
tations be performed at a small number of expe-
rienced heart transplantation centers where all 
remaining cardiological technologies are also avail-
able, because this will lead to more effective patient 
monitoring and adverse-effect management. In Po-
land, these should be 5 centers participating in the 
heart transplant program. Increasing the number 
of such sites is not necessary. In Germany, even 
though approximately 1000 LVADs are implanted 
each year, the mortality rate is high (about 33%). 
This is due to the fact that LVADs are implanted in 
over 40 centers, the majority of which do not run 
a heart transplant program. These centers do not 
perform such strict monitoring and management 
of adverse effects [1].
Estimation of the population of patients  
potentially eligible for LVAD DT
According to the 2018 map of health needs 
(Mapa potrzeb zdrowotnych), the incidence of HF 
in Poland is 364.1/100,000, which translates into 
140,000 new HF cases each year. The paper pub-
lished in 2018 entitled “Comprehensive care for 
patients with heart failure in Poland: suggested 
organizational solutions” reported the number of 
HF patients in Poland to be 750,000 [18]. 
According to clinical experts, in Poland, around 
200–300 LVADs should be implanted annually. This 
number should increase with improved LVAD avail-
ability. The newly created health service for LVAD 
implantation could be provided in 5 transplantation 
centers that would meet the criteria defined in the 
service description. Assuming that about 40 LVAD 
implantation procedures are performed per year 
per center, the initial annual number of LVAD im-
plantations can be estimated at 200 (with a gradual 
increase in the following years). Given the eligibil-
ity criteria for LVAD DT, it can be expected that 
the number of implantations with this indication 
will be around 100 per year in the initial period [1].
The use of LVADs and the reduction  
of lost patient productivity
In the group of working-age patients with 
LVADs, lost productivity due to the disease will be 
significantly reduced. Not only does LVAD implan-
tation extend patients’ lives compared to optimal 
medical care, but it also enables them to return to 
work, which is consistent with the improvement 
in health status demonstrated in clinical trials and 
expressed by the transition to lower NYHA func-
tional classes (from NYHA III/IV to NYHA I/II). 
The MOMENTUM study results regarding centrif-
ugal and axial pumps demonstrated that 12 months 
after LVAD implantation, the clinical status of 
81% of patients indicated they were in NYHA 
class I or II, while the baseline percentage of these 
patients was 0% [6, 19]. The use of LVADs will 
have an additional positive impact on the quality 
of life and productivity of patients’ close relatives 
and careers.
The heart transplant  
procedure situation in Poland
For many people, heart transplantation is the 
only effective treatment for end-stage HF. Patients 
can be qualified for transplantation if all treatment 
methods available to them have been exhausted, in-
cluding pharmacological and surgical ones, and if no 
significant contraindications for the procedure are 
identified. The most common cause of severe HF, 
which is an indication for a heart transplantation, is 
coronary heart disease and dilated cardiomyopathy, 
resulting from an inflammatory process or another 
cause, which is often impossible to determine. Less 
frequently identified HF is associated with valvular, 
congenital, or acquired malformations and other 
heart diseases [20].
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The final decision to qualify the patient for 
heart transplantation is made by the Heart Failure 
Heart Team (HFHT), which includes the following: 
an experienced cardiac surgeon, a transplantolo-
gist, a cardiologist, an anesthesiologist, a psycholo-
gist, a transplant coordinator, an LVAD coordinator, 
and a physiotherapist in the transplantation center. 
On the basis of the health status of the sick recipi-
ent, the qualification procedure is determined as: 
 — elective — patients with stable cardiovascular 
and respiratory status who receive conserva-
tive treatment for HF;
 — emergency — patients presenting with symp-
toms of severe HF despite specialist inpatient 
treatment; indications for inclusion in this list 
include intravenous therapy with drugs affect-
ing heart activity (e.g. catecholamines), MCS 
(IABP, LVADs/BiVADs), as well as refractory 
arrhythmias [20].
The rules for including patients on the POL-
TRANSPLANT National Waiting List are as fol-
lows: The recipient’s candidacy is reported to the 
National Waiting List kept by the POLTRANS-
PLANT Organization and Coordination Center for 
Transplantation Issues in Warsaw, which coordi-
nates, supervises, and manages the register of all 
cell, tissue, and organ transplantations in Poland. 
The entry is made by the Transplant Coordinator, 
who begins to monitor the recipient’s health on 
an ongoing basis from the moment the recipient 
is added to the list with particular attention to the 
following:
 — patient’s well-being and general health;
 — patient’s body weight;
 — patient’s international normalized ratio;
 — the procedure mode (elective/emergency) — if 
necessary, the Coordinator reports a change 
of the qualification mode to the POLTRANS-
PLANT National Waiting List and monitors the 
change of the qualification decision. 
The recipient entered in the National Waiting 
List is notified in writing of the entry into the Reg-
isters of Transplantations of the Ministry of Health 
by the POLTRANSPLANT Organization and Co-
ordination Center for Transplantation Issues [20].
In Poland, the number of patients awaiting 
a heart transplant is increasing year by year. Even 
though the number of heart transplants is also in-
creasing, it is still too low in relation to the demand. 
In 2018, 147 heart transplants were performed, 
and of these, only 23 procedures were scheduled, 
and the remaining ones were performed as an 
emergency. At the same time, experts indicate 
that existing transplant centers have the means 
to perform three times as many heart transplant 
procedures. The number of transplant centers 
should not be increased because the existing ones 
fully satisfy the country’s needs. It is estimated 
that a transplant center should perform at least one 
heart transplant per month to ensure optimal treat-
ment outcomes. In 2018, 326 new patients were 
registered for a heart transplant; however, in 2018 
alone, 100 patients from the list died while await-
ing a new heart. At the end of 2018, the number 
of patients waiting for a heart transplant was 453. 
Poland boasts (after the US) the highest number 
of hypoplastic left heart syndrome surgeries in the 
world. This defect results in a single ventricular 
heart and a possible heart transplant in the future. 
In total, 40% of patients with severe HF die within 
a year or require hospital readmission. This is 
a group with unmet needs for which just the use 
of an LVAD offers not only a chance for survival 
but also for a significant improvement in quality 
of life [1]. 
Major challenges of interventional  
cardiology: cardiogenic shock and high- 
-risk percutaneous coronary intervention
Poland is among Europe’s leading countries 
when it comes to the equipment in its interven-
tional cardiology centers. However, it is neces-
sary to invest in the use of percutaneous circu-
latory support pumps (e.g. Impella) for patients 
with cardiogenic shock and as hemodynamic 
support in high-risk percutaneous coronary 
intervention (protected percutaneous coronary 
intervention).
Cardiogenic shock, despite early coronary 
intervention, correction of mechanical defects, and 
the use of inotropic agents, is still a life-threatening 
complication of heart disease. Impaired end-organ 
perfusion caused by low cardiac output, if not 
reversed, leads to multiple organ dysfunction and 
death. One of the methods of treating cardiogenic 
shock is the use of MCS devices [21].
There are currently several types of these 
devices in use. They differ in their effectiveness 
and mechanism of operation, and can be divided 
into the following:
 — short-term MCS devices i.e. Impella and intra-
aortic balloon pump (IABP);
 — extracorporeal membrane oxygenation 
(ECMO);
 — implantable LVADs (e.g. HM3 LVAD) or bi-
ventricular assist devices,
 — total artificial heart [22].
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They differ, among other things, in the tech-
nique of insertion (percutaneous or surgical), the 
influence on individual heart structures (support 
of the left, right, or both ventricles), and in terms 
of the possibility of combined use with ECMO [22].
The 2018 ESC/EACTS guidelines on myocar-
dial revascularization list the following short-term 
MCS devices:
 — percutaneous LVAD;
 — veno-arterial ECMO; 
 — IABP, which may have a beneficial effect on 
some hemodynamic parameters, but does not 
improve survival; therefore, the routine use 
of IABPs in patients with cardiogenic shock 
complicating acute myocardial infarction is not 
recommended [23].
ECMO
Interventions performed to decrease left ven-
tricular workload include the following:
 — percutaneous — Impella (possible vascular 
complications due to access route);
 — surgical — ECMO:
• intermediate-term cardiac and respiratory 
support or respiratory support alone,
• can be used in a broad range of patients,
• percutaneous and direct implantation [1]. 
ECMO involves the use of extracorporeal 
circulation based on a modern centrifugal pump to 
oxygenate blood and eliminate carbon dioxide in 
the oxygenator. Extracorporeal circulation makes it 
possible to adjust the blood flow rate and accurately 
control its temperature. Blood is transported to and 
from the ECMO machine using a plastic cannula 
system. To reduce the risk of blood clot forma-
tion during ECMO, adequate anticoagulation is 
required with unfractionated heparin and activated 
partial thromboplastin time kept between 45 and 
60 seconds [24]. 
Depending on the underlying disease and the 
expected effect, two main ECMO circuit configura-
tions are used: 
 — veno-venous (VV), in which a cannula is placed 
into the jugular and/or femoral vein, or a spe-
cial dual-lumen cannula is inserted into the 
jugular vein. This set-up is used in cases of 
severe respiratory failure without circulatory 
dysfunction when the option of mechanical 
ventilation has been exhausted. The primary 
goal of this therapy is to provide the body with 
oxygen and eliminate carbon dioxide. Oxygen-
ated blood from the oxygenator is transported 
back to the venous system and then through 
the right ventricular myocardium to the lungs, 
left atrium, left ventricle, and aorta; 
 — veno-arterial (VA), which involves placing 
a venous cannula in the jugular and/or femoral 
vein and an arterial cannula in the femoral 
artery, ascending aorta, or subclavian artery. 
This type of vascular cannulation is used in 
cases of circulatory failure or concomitant 
cardiopulmonary dysfunction. If the decision to 
use ECMO during cardiac surgery is made, the 
cannulation can be performed directly through 
the chest (most often with cannulae placed in 
the right atrium and ascending aorta) — this 
is called central cannulation. The inflow of 
oxygenated blood to the arterial system with 
adequate kinetic energy generated by the 
ECMO pump supports the blood flow that the 
myocardium cannot provide [24].
In cases of respiratory failure, VV ECMO is 
used primarily in patients with severe pneumonia 
and acute respiratory distress syndrome. Indica-
tions for VA ECMO include the following: 
 — post cardiotomy;
 — shock in post-coronary artery bypass grafting 
patients; 
 — post-myocardial infarction VSD; 
 — de novo cardiogenic shock;
 — HF exacerbation;
 — primary graft dysfunction;
 — heart transplant rejection [1].
Experience with ECMO at the Institute of 
Cardiology in Warsaw: 
 — from 2013 to the end of 2019, mainly VA 
ECMO: n = 300 implantations (2013, n = 25 
Æ 2018, n = 63);
 — N = 133 deaths on ECMO (55.6%) (2013: 15 
deaths [60%] Æ 2018: 21 deaths [33.34%]).
ECMO in interventional cardiology is a uni-
versal tool because it can provide support during 
percutaneous coronary intervention and in cases 
of cardiogenic shock; in addition, it can be used 
simultaneously with IABP. Moreover, ECMO is 
an effective strategy for stabilizing critically ill 
patients as a bridge to long-term MCS. A 2019 ret-
rospective study demonstrated that in patients on 
ECMO support as a bridge to HM3 LVAD, survival 
to discharge was 81% [25]. The combined use of 
ECMO and Impella is also promising. When this 
system is used, Impella ensures additional left ven-
tricle unloading, optimizing ECMO operation [26]. 
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Conclusions
Patients with severe HF, especially those in 
NYHA class III/IV, who present with concomi-
tant diseases that preclude their qualification for 
a heart transplant, are a group with unmet needs 
in terms of survival, and they have poor functional 
status, various mobility limitations, and associ-
ated significantly reduced quality of life. Current 
optimal medical care provided with the use of 
pharmacological agents and medical devices such 
as implantable cardioverter-defibrillator and IABP 
is not enough to fulfil these needs. MCS based on 
LVAD DT is an alternative option for this patient 
population. The LVAD that will achieve the best 
clinical effectiveness as DT in this group of patients 
should be characterized above all by a very good 
hemocompatibility profile that will allow for long 
survival, free of events related to hemocompatibil-
ity, such as stroke, pump thrombosis, hemolysis, or 
other thromboembolic events. At the same time, 
this translates into a significant improvement in 
functional status and quality of life.
LVAD HM3 has all of the above-mentioned 
features of optimal DT in patients with severe HF, 
who do not qualify for a heart transplant. Its use 
enables patients to achieve significantly longer 
survival than with optimal medical management. 
In addition, the device meets the patients’ needs 
in terms of significantly improved functional status 
and quality of life. Positive outcomes achieved in 
patients not qualified for heart transplantation, 
who received the HM3 LVAD, are comparable 
with those in individuals qualifying for a heart 
transplant, who underwent HM3 implantation as 
a BTT/BTC. Technological progress and innovative 
technological solutions applied in the HM3 LVAD 
allow for a 2-year overall survival comparable to 
that achieved in patients with a heart transplant.
In a paper published in 2019, leading Pol-
ish experts in the field of cardiology and cardiac 
surgery indicated that the use of the HM3 LVAD 
would contribute to the improvement of patient 
survival, health-related quality of life, reduction 
of treatment costs, and limitation of the number 
of adverse cardiovascular events. They also indi-
cated that in Poland, pump implantation and heart 
transplantation are included in the same healthcare 
service. Therefore, there is no procedure available 
that would cover the costs of hospitalization follow-
ing a ventricular assist device implantation. It was 
emphasized that one of the measures that should 
be developed in order to increase patient access 
to HM3 technology is a public funding system ap-
propriate for this purpose [5]. 
Moreover, experts have indicated that cur-
rently the number of LVAD procedures, especially 
LVAD DT, is very limited. One of the reasons for 
this is excessively restrictive inclusion criteria and 
the lack of a separate service dedicated to LVAD 
DT. Experts recommend that the implantation of 
LVADs should be carried out in several Polish cent-
ers experienced in heart transplantations, because 
this will lead to more effective patient monitoring 
and adverse effect management.
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